Posted by Michael Wonder on 26 Mar 2024
Tonix Pharmaceuticals receives rare paediatric disease designation from the FDA for TNX-2900 for the treatment of Prader-Willi syndrome
25 March 2024 - TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating.
Tonix Pharmaceuticals today announced the US FDA has granted rare paediatric disease designation to TNX-2900 (intranasal potentiated oxytocin), a proprietary magnesium potentiated formulation of intranasal oxytocin, to treat Prader-Willi syndrome in children and adolescents.
